Andrea L Richardson

List of Publications by Year
in descending order

50 papers	18,898 citations	126907 33 h-index	223800 46 g-index
52 all docs	52 docs citations	52 times ranked	31208 citing authors

#	Article	IF	Citations
1	Signatures of mutational processes in human cancer. Nature, 2013, 500, 415-421.	27.8	8,060
2	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature, 2016, 534, 47-54.	27.8	1,760
3	Mutational Processes Molding the Genomes of 21 Breast Cancers. Cell, 2012, 149, 979-993.	28.9	1,673
4	HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nature Medicine, 2017, 23, 517-525.	30.7	769
5	X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell, 2006, 9, 121-132.	16.8	736
6	Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clinical Cancer Research, 2016, 22, 3764-3773.	7.0	733
7	Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nature Medicine, 2015, 21, 751-759.	30.7	711
8	Genomic Evolution of Breast Cancer Metastasis and Relapse. Cancer Cell, 2017, 32, 169-184.e7.	16.8	534
9	Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents. Cancer Discovery, 2012, 2, 366-375.	9.4	464
10	MicroRNA-Antagonism Regulates Breast Cancer Stemness and Metastasis via TET-Family-Dependent Chromatin Remodeling. Cell, 2013, 154, 311-324.	28.9	417
11	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
12	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
13	The topography of mutational processes in breast cancer genomes. Nature Communications, 2016, 7, 11383.	12.8	235
14	Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomarker Research, 2015, 3, 9.	6.8	214
15	Application of desorption electrospray ionization mass spectrometry imaging in breast cancer margin analysis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15184-15189.	7.1	207
16	Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine. Cell, 2016, 166, 126-139.	28.9	187
17	Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages. Nature Communications, 2020, 11, 1711.	12.8	134
18	BRCA1 haploinsufficiency for replication stress suppression in primary cells. Nature Communications, 2014, 5, 5496.	12.8	129

#	Article	IF	Citations
19	Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nature Communications, 2016, 7, 12910.	12.8	119
20	Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence. Nature Communications, 2015, 6, 7505.	12.8	101
21	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
22	The circular RNome of primary breast cancer. Genome Research, 2019, 29, 356-366.	5.5	85
23	Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents. Genome Biology, 2019, 20, 240.	8.8	82
24	Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency. Cancer Research, 2017, 77, 4755-4762.	0.9	81
25	A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers. Nature Genetics, 2017, 49, 341-348.	21.4	75
26	Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor. Cancer Cell, 2014, 26, 222-234.	16.8	71
27	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. Genome Research, 2015, 25, 814-824.	5.5	69
28	Subtype-specific accumulation of intracellular zinc pools is associated with the malignant phenotype in breast cancer. Molecular Cancer, 2016, 15, 2.	19.2	68
29	Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. Modern Pathology, 2021, 34, 1185-1193.	5.5	61
30	Protein Acyltransferase DHHC3 Regulates Breast Tumor Growth, Oxidative Stress, and Senescence. Cancer Research, 2017, 77, 6880-6890.	0.9	50
31	Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). Journal of Clinical Oncology, 2015, 33, 2623-2631.	1.6	49
32	Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation. Nature Communications, 2019, 10, 1749.	12.8	46
33	BEAMing Up Personalized Medicine: Mutation Detection in Blood. Clinical Cancer Research, 2012, 18, 3209-3211.	7.0	42
34	Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management. Histopathology, 2016, 68, 45-56.	2.9	37
35	Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ. Nature Communications, 2019, 10, 4182.	12.8	37
36	DNA Methylation Markers for Breast Cancer Detection in the Developing World. Clinical Cancer Research, 2019, 25, 6357-6367.	7.0	21

#	Article	IF	Citations
37	Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. Clinical Cancer Research, 2020, 26, 2704-2710.	7.0	21
38	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	2.5	18
39	RelA-Induced Interferon Response Negatively Regulates Proliferation. PLoS ONE, 2015, 10, e0140243.	2.5	16
40	Exploring Biomarkers of Phosphoinositide 3â€Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer. Oncologist, 2019, 24, 305-312.	3.7	11
41	BRCA1 deficiency specific base substitution mutagenesis is dependent on translesion synthesis and regulated by 53BP1. Nature Communications, 2022, 13, 226.	12.8	11
42	Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003.. Journal of Clinical Oncology, 2014, 32, 536-536.	1.6	5
43	Estrogen receptor (ER) signaling in normal, BRCA (B) 1 and B2 mutation associated, and ER-positive breast cancer (BC) mammary cells.. Journal of Clinical Oncology, 2012, 30, 576-576.	1.6	1
44	Genomic heterogeneity in primary breast cancer: Clinical implications.. Journal of Clinical Oncology, 2014, 32, 11004-11004.	1.6	1
45	TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)â€"Evaluating the homologous recombination deficiency (HRD) biomarker.. Journal of Clinical Oncology, 2014, 32, TPS1145-TPS1145.	1.6	1
46	Pathological Assessment Following Pre-operative Systemic Therapy. Current Breast Cancer Reports, 2011, 3, 197-204.	1.0	0
47	Distinctive lipid profiles of human breast cancer and adjacent normal tissues by desorption electrospray ionization mass spectrometry imaging.. Journal of Clinical Oncology, 2013, 31, 1132-1132.	1.6	0
48	Prospective clinical experience with research biopsies in breast cancer patients.. Journal of Clinical Oncology, 2013, 31, e17574-e17574.	1.6	0
49	Abstract B067: Taxonomy of breast cancer based on normal cell phenotype and ontology. , 2013, , .		0
50	Abstract P5-13-09: Identifying homologous recombination deficiency in breast cancer: Genomic instability score thresholds differ in breast cancer subtypes. Cancer Research, 2022, 82, P5-13-09-P5-13-09.	0.9	0